Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

Rhea-AI Summary

Biofrontera (Nasdaq: BFRI) will report fourth quarter and full year 2025 financial results after U.S. market close on Thursday, March 19, 2026. The company will host a conference call and webcast on March 19, 2026 at 10:00 a.m. ET to discuss results and provide a business update.

Dial-in numbers and a webcast link are provided for investor access.

News Market Reaction – BFRIW

-0.95%

1 alert

-0.95% News Effect

On the day this news was published, BFRIW declined 0.95%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions.

Conference Call and Webcast Information

Event:	Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call
Date:	Thursday, March 19, 2026
Time:	10:00 a.m. ET
Conference Call:	1-888-222-5806 (U.S.) 1-412-902-6516 (international)
Webcast:	Webcast – Biofrontera Inc. 4Q25 and Full Year 2025 Results Conference Call https://event.choruscall.com/mediaframe/webcast.html?webcastid=XTq1cPRZ

About Biofrontera Inc.

Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz^® with the RhodoLED^® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers¹. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate-to-severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to Biofrontera’s commercial opportunities and the commercial success of its products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz^® in combination with BF-RhodoLED^® and/or RhodoLED^® XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; the impact of any extraordinary external events; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor Relations

Ben Shamsian
646-829-9701
shamsian@lythampartners.com

¹ https://www.skincancer.org/skin-cancer-information/actinic-keratosis/

FAQ

When will Biofrontera (BFRI) release its Q4 and full year 2025 results?

Biofrontera will release Q4 and full year 2025 results after U.S. market close on March 19, 2026. According to the company, the announcement will occur following the close of U.S. financial markets, with a conference call scheduled the same day to review results and answer questions.

What time is the Biofrontera (BFRI) conference call on March 19, 2026?

The conference call is scheduled for 10:00 a.m. Eastern Time on March 19, 2026. According to the company, the call will follow the results release and include a business update and a Q&A session for investors and analysts.

How can investors join the Biofrontera (BFRI) March 19, 2026 webcast?

Investors can join the webcast via the provided Chorus Call URL on March 19, 2026. According to the company, the webcast link is available for live listening and will cover the Q4 and full year 2025 results and management commentary.

What phone numbers can U.S. and international participants use for the Biofrontera (BFRI) call?

U.S. participants can call 1-888-222-5806; international callers can use 1-412-902-6516. According to the company, both dial-in numbers will connect participants to the March 19, 2026 conference call discussing 2025 financial results and a business update.

Will Biofrontera (BFRI) provide a business update during the March 19, 2026 call?

Yes. The company will provide a business update during the March 19, 2026 conference call alongside the financial results discussion. According to the company, management intends to discuss recent developments and answer investor questions during the scheduled call and webcast.

Where can I find the recording or replay of the Biofrontera (BFRI) March 19, 2026 presentation?

A replay or recording is typically available via the company's webcast link or investor relations page after the live call. According to the company, the webcast page provided for the March 19, 2026 event should host the live stream and subsequent on-demand replay.